文献速递生殖医学

单次口服维生素D3补充对正常体重女性IVF-ET结局的影响:SUNDRO随机对照试验

Single oral dose of vitamin D3 supplementation prior to in vitro fertilization and embryo transfer in normal weight women: the SUNDRO randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-21

SUNDRO试验为双中心、随机、双盲、安慰剂对照的优效性研究,纳入630例低维生素D、正常体重、卵巢储备尚可且进入IVF/ICSI周期的女性。结果显示,单次口服600,000 IU维生素D3与安慰剂相比未改善临床妊娠率(37% vs 40%,P=.37;RR 0.91,95%CI 0.75-1.11)。

要点

  • 单次口服600,000 IU维生素D3未改善IVF周期临床妊娠率。
  • 临床妊娠率治疗组37%、安慰剂组40%,差异无统计学意义。
  • 亚组分析未发现可从补充中获益的临床情形。

核心结论

  • 在正常体重、卵巢储备尚可且低维生素D水平的IVF女性中,单次口服600,000 IU维生素D3未改善临床妊娠率。

研究设计与样本

  • SUNDRO为双中心随机优效性双盲安慰剂对照试验,2016年10月至2019年1月招募630例18-39岁女性。
  • 纳入标准包括外周25-羟基维生素D<30 ng/mL、血清钙≥10.6 mg/dL、BMI 18-25 kg/m2、AMH>0.5 ng/mL且进入第1-3个常规IVF或ICSI周期。
  • 受试者随机接受单次600,000 IU维生素D3(n=308)或安慰剂(n=322),主要分析按意向性治疗进行。

主要发现

  • 治疗组113例(37%)与安慰剂组130例(40%)获得临床妊娠,P=.37。
  • 维生素D3组临床妊娠的风险比为0.91(95%CI 0.75-1.11)。
  • 探索性亚组分析(BMI、年龄、IVF指征、卵巢储备、给药至周期启动间隔、基线25-羟基维生素D水平)未发现可从补充中获益的情形。

关键数值与推荐

  • 主要结局为每周期累积临床妊娠率,临床妊娠定义为宫内妊娠囊且可见存活胎儿。
  • 次要结局包括促性腺激素总剂量、胚胎学变量(获卵数、合适卵数、受精率、优质胚胎率)及临床结局(流产率、活产率)。

临床怎么用

  • 不推荐仅为提高IVF成功率而对正常体重、低维生素D女性常规给予单次600,000 IU维生素D3。
  • 临床决策应结合患者个体情况,不将维生素D补充作为改善IVF妊娠率的常规干预。

局限性

  • 研究未排除更温和但可能具有临床意义的获益,需进一步研究。
  • 需探索其他补充方式的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improving in vitro fertilization success is an unmet need. Observational studies have suggested that women with deficient or insufficient vitamin D have lower chances of in vitro fertilization success, but whether supplementation improves clinical pregnancy rate remains unclear. OBJECTIVE: This study aimed to determine whether oral vitamin D3 supplementation improves clinical pregnancy in women undergoing an in vitro fertilization cycle. STUDY DESIGN: The "supplementation of vitamin D and reproductive outcome" trial is a 2-center randomized superiority double-blind placebo-controlled trial. Subjects were recruited between October 2016 and January 2019. Participants were women aged 18 to 39 years with low vitamin D (peripheral 25-hydroxyvitamin D of <30 ng/mL), serum calcium of ≥10.6 mg/dL, body mass index of 18 to 25 kg/m2, and antimüllerian hormone levels of >0.5 ng/mL and starting their first, second, or third treatment cycle of conventional in vitro fertilization or intracytoplasmic sperm injection. The primary outcome was the cumulative clinical pregnancy rate per cycle. Pregnancies obtained with both fresh or frozen embryo transfers were included. Clinical pregnancy was defined as an intrauterine gestational sac with a viable fetus. The primary analysis was performed according to the intention-to-treat principle and could also include natural conceptions. Secondary outcomes included total dose of gonadotropins used, embryologic variables (number of oocytes retrieved, number of suitable oocytes retrieved, fertilization rate, and rate of top-quality embryos), and clinical outcomes (miscarriage rate and live birth rate). RESULTS: Overall, 630 women were randomized 2 to 12 weeks before the initiation of the in vitro fertilization cycle to receive either a single dose of 600,000 IU of vitamin D3 (n=308) or placebo (n=322). Interestingly, 113 (37%) and 130 (40%) women achieved a clinical pregnancy in the treatment and placebo groups, respectively (P=.37). The risk ratio of clinical pregnancy in women receiving vitamin D3 was 0.91 (95% confidence interval, 0.75-1.11). Compared with the placebo, vitamin D3 supplementation did not improve the rate of clinical pregnancy. Exploratory subgroup analyses for body mass index, age, indication to in vitro fertilization, ovarian reserve, interval between drug administration and initiation of the cycle, and basal levels of 25-hydroxyvitamin D failed to highlight any clinical situation that could benefit from the supplementation. CONCLUSION: In women with normal weight with preserved ovarian reserve and low vitamin D levels undergoing in vitro fertilization cycles, a single oral dose of 600,000 IU of vitamin D3 did not improve the rate of clinical pregnancy. Although the findings do not support the use of vitamin D3 supplementation to improve in vitro fertilization success rates, further studies are required to rule out milder but potentially interesting benefits and explore the effectiveness of alternative modalities of supplementation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Somigliana E, Sarais V, Reschini M, et al. Single oral dose of vitamin D3 supplementation prior to in vitro fertilization and embryo transfer in normal weight women: the SUNDRO randomized controlled trial. Am J Obstet Gynecol. 2021. PMID: 33894153. doi:10.1016/j.ajog.2021.04.234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。